Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 2014 of 6351
-
Triple immunotherapy cocktail shows promise in tough cancers
Disease control CompletedThe study will determine Recommended Phase 2 Dose for all study drugs, based on the safety and tolerability of the following combinations: INCAGN02385 + INCAGN02390 and INCAGN02385 + INCAGN02390 + INCMGA00012.
Phase 1/2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New Nerve-Zapping procedure tested for back pain relief
Symptom relief OngoingThis is an independent prospective, noninterventional, observational post-market data collection of the patient-reported effectiveness, ongoing safety and satisfaction outcomes for patients treated with the Intracept Procedure at a single study site.
Sponsor: University of Utah • Aim: Symptom relief
Last updated Jun 27, 2026 12:06 UTC
-
Experimental drug targets tough blood cancers in first human trial
Disease control Stopped earlyPrimary Objective: To determine the maximum tolerated dose (MTD) of SAR442257 administered as a single agent in patients with relapsed and refractory multiple myeloma (RRMM) and relapsed and refractory non-Hodgkin lymphoma (RR-NHL), and determine the recommended Phase 2 dose (RP…
Phase 1 • Sponsor: Sanofi • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New weekly shot shows promise for rare bleeding disorder
Disease control CompletedTo select a dose and to make a decision for Phase 3 study
Phase 2/3 • Sponsor: Harbour BioMed (Guangzhou) Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Can vitamin c save burn victims? major trial halted midway
Disease control PausedThis study aims to show that giving high dose, intravenous vitamin C in addition to standard care to burned critically ill patients will be associated with less organ dysfunction, improved survival and a quicker rate of recovery. In this study, all patients will receive standard …
Phase 3 • Sponsor: Clinical Evaluation Research Unit at Kingston General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New drug combo targets Hard-to-Treat cancers
Disease control CompletedThe primary purpose of this study is to define the maximum tolerated dose (MTD) and determine a recommended Phase 2 dose (RP2D) and schedule of orally-administered RP-3500 (camonsertib) alone or in combination with talazoparib, a PARP inhibitor, or Gemcitabine in patients with ad…
Phase 1/2 • Sponsor: Repare Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control CompletedThe main aim of this study is to check if people with advanced solid tumors have side effects from dazostinag, and to check how much dazostinag they can receive without getting significant side effects from it when given alone and in combination with pembrolizumab. The study will…
Phase 1/2 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New biosimilar shows promise for treating wet macular degeneration
Disease control CompletedThis is a randomized, double-masked, multicenter study to evaluate the efficacy and safety of FYB203 compared to Eylea® in patients with neovascular age related macular degeneration.
Phase 3 • Sponsor: Bioeq GmbH • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Stem cell hope for rare brain disease: 20 patients tracked
Disease control By invitation onlyThe purpose of this study is to measure the effect of Hematopoietic Stem Cell Transplantation (HSCT) on symptoms of CSF1R-related Leukoencephalopathy.
Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New drug combo targets tough blood cancers
Disease control OngoingThis phase I/II trial studies the side effects and best dose of quizartinib when given with azacitidine and to see how well they work in treating patients with myelodysplastic syndrome or myelodysplastic/myeloproliferative neoplasm with FLT3 or CBL mutations. Chemotherapy drugs, …
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Better sleep, better stroke recovery? new study tests simple hospital changes
Symptom relief CompletedGiven the critical role of sleep in enhancing neural recovery, motor learning, neuroprotection, and neuroplasticity, interventions to enhance sleep that target sleep could improve recovery and rehabilitation outcomes for stroke patients. In this proposal, a multidisciplinary grou…
Sponsor: University of Chicago • Aim: Symptom relief
Last updated Jun 27, 2026 12:07 UTC
-
Experimental combo targets Hard-to-Treat gut tumors
Disease control OngoingThis phase I trial studies the side effects and best dose of triapine when given together with lutetium Lu 177 dotatate in treating patients with neuroendocrine tumors. Triapine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radioactive…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Immune cell combo shows promise in tough head and neck cancers
Disease control CompletedThis research study is evaluating the safety and efficacy of a combination drug and biologic therapy in patients with advanced head and neck cancer. This research study involves the following drugs and biologics: * CIML NK donor cells * IL-15 superagonist * Ipilimumab * Cetuxim…
Phase 1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
New drug shows promise for kidney disease in phase 2 trial
Disease control CompletedThe purpose of this study is to evaluate the efficacy and safety of VIS649 in participants with immunoglobulin A (IgA) Nephropathy (IgAN)
Phase 2 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Could donor stem cells repair hearts damaged by chemo?
Disease control PausedThis randomized pilot phase I trial studies the side effects of donor bone marrow derived mesenchymal stem cells in controlling heart failure in patients with cardiomyopathy caused by anthracyclines. Donor bone marrow derived mesenchymal stem cells may help to control symptoms of…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Can blood pressure meds after delivery keep new moms out of the hospital?
Disease control OngoingThe goal of this study is to compare whether antihypertensive treatment in the postpartum period decreases postpartum hypertension and its associated maternal morbidity, including risk of readmission and healthcare utilization in comparison with no treatment. Women with preeclamp…
Phase 3 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New drug BT8009 targets Hard-to-Treat cancers in early trial
Disease control OngoingThis study is a Phase I/II, multicenter, first-in-human, open-label dose-escalation study of BT8009 given as a single agent and in combination with pembrolizumab in participants with advanced solid tumors associated with Nectin-4 expression or in participants with advanced solid …
Phase 1/2 • Sponsor: BicycleTx Limited • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Tracking superbugs from mother to baby: a chicago study
Knowledge-focused CompletedThe investigators aim to conduct a prospective surveillance study of mothers and their infants born vaginally or by scheduled C-section and who are admitted to Northwestern Medicine Prentice Women's Hospital to determine the prevalence of ESBL-E carriage in healthy post-partum wo…
Sponsor: Ann & Robert H Lurie Children's Hospital of Chicago • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
Can dupilumab heal the skin barrier in eczema patients?
Disease control CompletedPrimary Objective: \- Evaluate changes in skin barrier function with transepidermal water loss (TEWL) assessed after skin tape stripping (STS) in pre-defined lesional skin in participants with moderate to severe atopic dermatitis (AD) treated with dupilumab. Secondary Objective…
Phase 4 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 26, 2026 18:46 UTC
-
Old polio vaccine may offer new shield against COVID-19
Disease control CompletedSince the 1960s, studies have shown that oral polio vaccine (OPV) may have beneficial non-specific effects, reducing morbidity and mortality from other infections than polio. Such beneficial non-specific effect have been observed for other live vaccines, including measles, smallp…
Phase 4 • Sponsor: Bandim Health Project • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC